Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries
Up to 80% of antibiotics are prescribed in the community. An assessment of prescribing by indication will help to identify areas where improvement can be made. A point prevalence audit study (PPAS) of consecutive respiratory tract infection (RTI) consultations in general practices in 13 European countries was conducted in January-February 2020 (PPAS-1) and again in 2022 (PPAS-4). The European Surveillance of Antibiotic Consumption quality indicators (ESAC-QI) were calculated to identify where improvements can be made. A total of 3618 consultations were recorded for PPAS-1 and 2655 in PPAS-4. Bacterial aetiology was suspected in 26% (PPAS-1) and 12% (PPAS-4), and an antibiotic was prescribed in 30% (PPAS-1) and 16% (PPAS-4) of consultations. The percentage of adult patients with bronchitis who receive an antibiotic should, according to the ESAC-QI, not exceed 30%, which was not met by participating practices in any country except Denmark and Spain. For patients (≥1) with acute upper RTI, less than 20% should be prescribed an antibiotic, which was achieved by general practices in most countries, except Ireland (both PPAS), Croatia (PPAS-1), and Greece (PPAS-4) where prescribing for acute or chronic sinusitis (0-20%) was also exceeded. For pneumonia in adults, prescribing is acceptable for 90-100%, and this is lower in most countries. Prescribing for tonsillitis (≥1) exceeded the ESAC-QI (0-20%) in all countries and was 69% (PPAS-1) and 75% (PPAS-4). In conclusion, ESAC-QI applied to PPAS outcomes allows us to evaluate appropriate antibiotic prescribing by indication and benchmark general practices and countries.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Antibiotics (Basel, Switzerland) - 12(2023), 3 vom: 14. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vellinga, Akke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibiotic prescribing |
|---|
| Anmerkungen: |
Date Revised 31.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/antibiotics12030572 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354834029 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354834029 | ||
| 003 | DE-627 | ||
| 005 | 20231226063052.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/antibiotics12030572 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1182.xml |
| 035 | |a (DE-627)NLM354834029 | ||
| 035 | |a (NLM)36978439 | ||
| 035 | |a (PII)572 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vellinga, Akke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Up to 80% of antibiotics are prescribed in the community. An assessment of prescribing by indication will help to identify areas where improvement can be made. A point prevalence audit study (PPAS) of consecutive respiratory tract infection (RTI) consultations in general practices in 13 European countries was conducted in January-February 2020 (PPAS-1) and again in 2022 (PPAS-4). The European Surveillance of Antibiotic Consumption quality indicators (ESAC-QI) were calculated to identify where improvements can be made. A total of 3618 consultations were recorded for PPAS-1 and 2655 in PPAS-4. Bacterial aetiology was suspected in 26% (PPAS-1) and 12% (PPAS-4), and an antibiotic was prescribed in 30% (PPAS-1) and 16% (PPAS-4) of consultations. The percentage of adult patients with bronchitis who receive an antibiotic should, according to the ESAC-QI, not exceed 30%, which was not met by participating practices in any country except Denmark and Spain. For patients (≥1) with acute upper RTI, less than 20% should be prescribed an antibiotic, which was achieved by general practices in most countries, except Ireland (both PPAS), Croatia (PPAS-1), and Greece (PPAS-4) where prescribing for acute or chronic sinusitis (0-20%) was also exceeded. For pneumonia in adults, prescribing is acceptable for 90-100%, and this is lower in most countries. Prescribing for tonsillitis (≥1) exceeded the ESAC-QI (0-20%) in all countries and was 69% (PPAS-1) and 75% (PPAS-4). In conclusion, ESAC-QI applied to PPAS outcomes allows us to evaluate appropriate antibiotic prescribing by indication and benchmark general practices and countries | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antibiotic prescribing | |
| 650 | 4 | |a audit | |
| 650 | 4 | |a primary health care | |
| 650 | 4 | |a quality in healthcare | |
| 650 | 4 | |a respiratory infections | |
| 700 | 1 | |a Luke-Currier, Addiena |e verfasserin |4 aut | |
| 700 | 1 | |a Garzón-Orjuela, Nathaly |e verfasserin |4 aut | |
| 700 | 1 | |a Aabenhus, Rune |e verfasserin |4 aut | |
| 700 | 1 | |a Anastasaki, Marilena |e verfasserin |4 aut | |
| 700 | 1 | |a Balan, Anca |e verfasserin |4 aut | |
| 700 | 1 | |a Böhmer, Femke |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Valerija Bralić |e verfasserin |4 aut | |
| 700 | 1 | |a Chlabicz, Slawomir |e verfasserin |4 aut | |
| 700 | 1 | |a Coenen, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a García-Sangenís, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalczyk, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Malania, Lile |e verfasserin |4 aut | |
| 700 | 1 | |a Tomacinschii, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a van der Linde, Sanne R |e verfasserin |4 aut | |
| 700 | 1 | |a Bongard, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Christopher C |e verfasserin |4 aut | |
| 700 | 1 | |a Goossens, Herman |e verfasserin |4 aut | |
| 700 | 1 | |a van der Velden, Alike W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antibiotics (Basel, Switzerland) |d 2012 |g 12(2023), 3 vom: 14. März |w (DE-627)NLM243235135 |x 2079-6382 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:3 |g day:14 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/antibiotics12030572 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 3 |b 14 |c 03 | ||